Abstract

Oromandibular dystonia (OMD) is a clinical problem which is commonly encountered in the practice of movement disorders. OMD results from a variety of genetic and acquired etiologies and can occur as an isolated manifestation, or as part of an isolated generalized or a combined dystonia syndrome. There are only very few systematic reviews on this condition which often causes significant disability. We review here the etiology, clinical features, diagnostic approach and management of OMD.

Keywords: Approach, etiology, oromandibular dystonia

Introduction

Cranial dystonia may involve the upper face or the lower face, jaw, tongue and pharynx. Cranial dystonia involving the upper part of face includes blepharospasm, oculogyric crisis, and frontalis dystonia. The term oromandibular dystonia (OMD) is used to denote lower cranial dystonia, involving the muscles of the lower face, jaw, tongue and pharynx. OMD commonly occurs together with blepharospasm, and the combination is generally called Meige syndrome. OMD can be seen in a variety of scenarios, either in isolation, as part of a more widespread dystonia, or as a part of a combined dystonia syndrome with a broader clinical presentation. Identification of lower cranial dystonia in isolated generalized and combined dystonia syndromes guides etiological diagnosis, because of its association with specific etiologies. In this review, we will discuss the clinical features, etiology, and approach to diagnosis and management of oromandibular dystonia.

Search Strategy

Relevant studies on OMD were reviewed using PubMed search. The key words “oromandibular dystonia”, “lower cranial dystonia,” “facial dystonia,” “oro facial dystonia,” “mandibular dystonia,” and “lingual dystonia” were used and articles published till 5th October 2020 were considered. A total of 65 articles on “lower cranial dystonia,” 1142 articles on “facial dystonia” (122 on “lower facial dystonia”), 175 articles on “oro facial dystonia,” 147 articles on “mandibular dystonia,” 405 articles on “oromandibular dystonia,” and 287 articles on “lingual dystonia” were found. The abstracts were reviewed by the authors and articles relevant for this review were selected.

Epidemiology and Demographic Features

The prevalence of OMD is estimated to be 68.9 cases/million. The onset of OMD peaks in the sixth decade of life. Women are almost twice as frequently affected as men. Hormonal factors probably play a role in this; an interesting, 12-year follow up of a patient with OMD highlighted the influence of hormonal factors on OMD, with severity of symptoms varying in different phases of menstrual cycle.

Etiological Factors

Most cases of OMD occur in combination with blepharospasm or dystonia in other body parts, manifesting as an isolated phenomenon only in 2–23% of the cases. In the largest study on OMD till date, only 34.2% of patients had focal OMD whereas 54.6% had OMD as part of segmental dystonia and 11.3% presented with generalized dystonia.

“Primary” (Dystonia presenting and remaining as an isolated phenomenon, without evidence of neurodegeneration, structural brain damage or other detectable non-genetic etiology) or idiopathic dystonia due to a genetic or presumed genetic cause is the commonest etiology subtype of OMD, accounting for >60% of cases. Tardive dystonia (drug-induced) is the most common cause of secondary OMD, reported in 22.8% of the cases. Other described causes are peripheral-induced OMD (related to orofacial trauma) in 9.3% of the cases, post-anoxic states in 2.5%, neurodegenerative disorders in 1.8%, and head injury-associated OMD in 0.9%. However, in a large series of lingual dystonia, 41% of cases were reported...
to be secondary to medications, 18% were associated with heredodegenerative conditions and post-encephalitic state, 12% occurred as part of isolated generalized dystonia and 29% were focal and presumed to be “primary.”

**Clinical Features**

Dystonia is defined as a movement disorder characterized by sustained or intermittent muscle contractions causing abnormal, often repetitive, movements, postures, or both. Dystonic movements are typically patterned, twisting, and may be tremulous, are often initiated or worsened by voluntary action and are associated with overflow muscle activation. Dystonia is classified along two axes: clinical characteristics and etiology. Clinically, dystonia may be either isolated (Dystonia, with or without dystonic tremor, being the only abnormality on neurological examination) or combined (Dystonia with other movement disorders, neurological examination abnormalities or evidence of systemic involvement). A careful clinical examination and confirmation of clinical phenomenology of dystonia and associated neurological and systemic features help to arrive at a syndromic diagnosis, narrow down the etiological possibilities and guide diagnostic investigations.

Oromandibular dystonia has to be differentiated from chorea involving the lower facial muscles. Cranial dystonia usually consists of prolonged movements and postures, which are distressing to the patient, and cause functional disability. On the contrary, orofacial chorea consists of brief and non-patterned movements, which may not be distressing to the patient and does not cause functional disability. Similar to OMD, facial dystonic tics are often patterned, but associated sensory phenomena, urge to perform the movements and relief after performing the movements will help to make the correct phenomenological diagnosis.

OMD consists of sustained or intermittent involuntary, repetitive, patterned muscle contractions affecting the lower part of the face, mouth, jaw, tongue, and pharynx. It can be associated with difficulties in speaking, chewing, swallowing, and even breathing. Usual triggers include stress, speaking and swallowing. The first symptom is usually precipitated by specific movements or actions (action dystonia), later on progressing to involve additional actions and then occurring at rest and the spasms becoming more intense. Morning benefit (milder symptoms during morning) and overflow phenomenon (activation of muscles which are not otherwise involved, during certain tasks) are relatively common. OMD can be subdivided into different subtypes: jaw-opening dystonia, jaw-closing dystonia, jaw-deviating dystonia, perioral dystonia, and/or lingual dystonia. Jaw opening dystonia is caused by sustained contractions of the lateral pterygoid muscles presenting as involuntary opening and/or inability to close the mouth. Prolonged jaw opening results in difficulty with mastication, swallowing and causes drooling. Patients have difficulty articulating and may have unintelligible speech.

Jaw closing dystonia can occur alone, or in association with jaw opening dystonia. Sustained contractions of the masseter and/or temporalis muscles result in trismus and jaw clenching. Forced jaw closure may damage the lips, gums, tongue and buccal mucosa. Teeth may be cracked, and it may be impossible to maintain dentures in place. Temporomandibular joint pain may occur, along with recurrent jaw dislocation. Jaw closing dystonia has been described in musicians who play wind instruments and develop task-specific dystonia in response to attempting to play their instrument.

Isolated OMD is often misdiagnosed as dental problems, bruxism or temporomandibular joint disorders. The association of OMD with temporomandibular joint disorders is also known. Occasionally, OMD may be asymmetrical or even unilateral, thus mimicking hemifacial spasm or hemi‑masticatory spasm.

OMD could lead to secondary complications and these should be looked for while examining the patient. It can cause dysphagia, speech disorders, subluxation of the temporomandibular joint, deviation of the mandible, and soft-tissue trauma intraorally. Occlusal relationship may change and significant weight loss can occur due to poor oral intake.

Muscles of the pharynx and larynx may also be involved in patients with OMD; larynx is considered as a separate body region and not part of cranial dystonia in the current classification of dystonia. When larynx is involved, the voice may become harsh, hoarse and strained, a condition termed spasmodic dysphonia. Cervical dystonia is also a common accompaniment of OMD; less often distal muscles, such as those of the upper limbs may also be affected. The upper limb dystonia may manifest as dystonic tremor alone and posturing may not be evident. Careful examination for additional neurological examination abnormalities like parkinsonism, pyramidal signs, ataxia and polyneuropathy should be done in all patients as these are often seen in patients with OMD resulting from conditions causing progressive neurodegeneration or structural damage.

**Clues to Etiological Diagnosis**

The conditions which cause OMD, either as an isolated phenomenon, part of a generalized dystonia syndrome, or as part of more diffuse neurological involvement, are listed in Tables 1 and 2. Though the list is long, careful analysis of the clinical characteristics (e.g., age at onset, temporal course, additional body regions affected and additional neurologic and systemic features) help to narrow down the differentials and tailor the battery of diagnostic investigations for the individual patient.

Isolated OMD in adulthood with or without spread to cranio-cervical region suggests a genetic etiology, without neurodegeneration or structural brain damage (“primary” dystonia). Cranial dystonia with onset in childhood and adolescence, even if isolated at onset, generally evolves
This corroborates with finding [43][21][54]
Promethazine, [49] VPS16, [50] THAP1
In a study comparing [24][41][38]
Prkra [42][18][27][28][37][34][30]
Anti-Yo, IgLON5
TAF1 [47][8][45][36][55]
HPCA [44][33]
CNS toxoplasmosis
Lithium
West Nile Virus, Varicella Zoster,
Acquired hepatocerebral degeneration (Sertraline, Citalopram, Venlafaxine, Fluoxetine, Paroxetine, Amoxapine)

Sensory tricks are also described [52]
Levofloxacin
Betahistine, [40] COL6A3

In patients with [26] Lamotrigine
Anticonvulsants (Phenytoin, Sodium Valproate, Carbamazepine, Lamotrigine)

Anti-emetics (Metoclopramide, Sulpiride, Domperidone, Cisapride)
Antibiotics (Cefixime, [19][20][48]
Levofloxacin[20]
Cetirizine,[21] Betahistine,[22] Promethazine,[21] Prochlorperazine,
Dextromethorphan[20]
Anaesthetic agents (Propofol, Sevoflurane, Fentanyl, Nitrous oxide[23][25]
Capcetibine[26]
L-dopa, Methylphenidate,[27] Lithium
Alcohol, manganese, mercury, Carbon monoxide poisoning, glue sniffing
Metabolic/Endocrine
Kernicterus[28]
Hypoparathyroidism
Extrapontine myelinolysis[29]
Uremia,[30] acquired hepatocerebral degeneration[31]
Cerebral Palsy/Post hypoxic encephalopathy[32]

Autoimmune/paraneoplastic
SLE, APLA syndrome, Sjogren syndrome, Behcet syndrome,[33] Coeliac disease
Anti-NMDA, LGI-1, CASPR2 encephalitis
anti-Hu, anti-Ri,[34] anti-Yo, IgLON5
Satoyoshi syndrome[35]

Infections
HIV encephalitis,[36] CNS toxoplasmosis
Tuberculosis[37]
SSPE,[38] variant CJD
Mycoplasma,[39] West Nile Virus, Varicella Zoster,[40] Mumps, Japanese Encephalitis[41]

Structural
Vascular (ischemic or hemorrhagic stroke) – Basal ganglia/cerebellum/thalamus[42]
Brainstem neoplasm
Brainstem demyelination

Others
Traumatic brain injury
Radiation therapy[43]
Facial trauma
Functional

Table 1: Acquired causes of OMD

| Drugs & toxins |
|---------------|
| Neuroleptics-typical and atypical (Acute and Tardive) |
| Antidepressants[43] (Sertraline, Citalopram, Venlafaxine, Fluoxetine, Paroxetine, Amoxapine) |
| Anticonvulsants (Phenytoin, Sodium Valproate, Carbamazepine, Lamotrigine) |
| Anti-emetics (Metoclopramide, Sulpiride, Domperidone, Cisapride) |
| Antibiotics (Cefixime, [19] Levofloxacin[20]) |
| Cetirizine,[21] Betahistine,[22] Promethazine,[21] Prochlorperazine, Dextromethorphan[20] |
| Anaesthetic agents (Propofol, Sevoflurane, Fentanyl, Nitrous oxide[23][25]) |
| Capcetibine[26] |
| L-dopa, Methylphenidate,[27] Lithium |
| Alcohol, manganese, mercury, Carbon monoxide poisoning, glue sniffing |

Table 2: Genetic causes of OMD

| Autosomal dominant |
|-------------------|
| DYT-THAP1, DYT-TAF1, DYT-ATP1A3, DYT-KMT2B, DYT-PRKRA, DYT-TOR1* |
| DYT-CIZ1, DYT-ANO3, DYT-GNAL |

Spino cerebellar ataxia 1,2,3,8,12,36
Neuroferritinopathy

Autosomal recessive
Pantothenate kinase associated neurodegeneration
Wilson’s disease
Chorea-acanthocytosis
Aceruloplasminemia
Niemann-Pick C
Gaucher disease
GM2 gangliosidosis
Type II GM1 gangliosidosis
Tay-Sachs disease
Friedreich’s ataxia[44]
Ataxia telangiectasia
Cerebrotendinous xanthomatosis
Methylmalonic aciduria[45]
Glutaric aciduria type 1
Dopa-responsive dystonia
Dopamine transporter deficiency syndrome[46]
Hypermanganesemia with dystonia-1[47]
Fahr’s disease
DYT-COL6A3, DYT-HPCA, DYT-VPS16
Woodhouse Sakati syndrome
COASY protein-associated neurodegeneration
Mitochondrial membrane protein-associated neurodegeneration

X-linked
Lesch Nyhan syndrome
McLeod syndrome[48]
Mitochondrial
Leigh syndrome
Deafness-dystonia syndrome[49]

* Prominent OMD is unusual but could be seen in some patients with more severe manifestations

into combined dystonia syndromes, and degenerative/heredo-degenerative etiologies are more likely.[50]

Tongue bite is encountered in tardive and idiopathic OMD and OMD associated with neurodegenerative etiologies like neuro-acanthocytosis, but not associated with the movement pattern in edentulous dyskinesia.[51] In a study comparing tardive with idiopathic OMD, oro-facial-lingual stereotypic movements were significantly more frequent in the tardive group. Presence of stereotypic movements in the limbs, akathisia, and respiratory dyskinesias in patients with OMD further suggests tardive etiology. Dystonia in tardive OMD was more likely to be restricted to the oromandibular region, whereas in patients with idiopathic OMD, there was often coexistent cervical dystonia.[8] This corroborates with finding of spread in isolated focal dystonia in a prospective cohort.[52]

Dystonic tremor of the jaw and lips is described in embouchure dystonia and posttraumatic oromandibular dystonia, in addition to primary OMD.[53]

Geste antagoniste (sensory tricks) are usually observed in “primary dystonia,”[54] but have also been described rarely in some heredodegenerative conditions and dystonia associated with structural brain damage.[55] In patients with Pantothenate kinase-associated neurodegeneration (PKAN), a characteristic geste antagoniste for oromandibular (jaw opening) dystonia – touching chin with both hands – has been proposed as “mantis sign”.[56] Sensory tricks are also described in post-traumatic OMD.[57]
Singers have been described with spasmodic dysphonia but task-specific oromandibular dystonia are less common. Reported task-specific oromandibular dystonia include embouchure dystonia,[58] chewing-induced,[59] auctioneer’s jaw,[60] and prayer-induced dystonia.[61]

**Acquired Disorders**

Drug-induced OMD is the commonest acquired cause, with dopamine receptor blocking agents being the commonest drug group implicated. Other drugs precipitating OMD are listed in Table 1. Brainstem lesions due to demyelination or tumor, and ischemic and hemorrhagic stroke involving basal ganglia, thalamus or cerebellum, can cause OMD.[62]

Autoimmune encephalitis should be considered in the appropriate clinical scenario as it is imminently treatable. Anti-NMDA, anti-LGI1 and anti-Ri have been classically associated with oromandibular dystonia, but it has also been described in anti-Ma2[63] and anti-IgLON5.[64] Other immune disorders like Celiac disease,[65] Sjogren’s syndrome[66] and lupus[67] presenting with OMD have also been described. The infections which are reported to present with OMD include CNS toxoplasmosis and Japanese encephalitis, which have a predilection to involve basal ganglia. Oromandibular-facial trauma, dental procedures and parotid gland surgery have been reported to precipitate and exacerbate OMD.[68,69] This has been termed as peripherally induced OMD, although the physiological and biochemical mechanisms are not well understood.[57] OMD can occur as sequelae of traumatic brain injury and hypoxic injury; OMD can be a prominent feature in children with dystonic cerebral palsy (CP), though isolated OMD as a manifestation of perinatal hypoxia is rare.

**Genetic Causes**

Table 2 lists the genetic disorders which have OMD as part of clinical spectrum. Among the genetic causes presenting and remaining as isolated dystonia (erstwhile “primary dystonia”), involvement of lower cranial musculature helps in narrowing differential diagnosis. Genetic OMDs with onset in childhood-adolescence are likely to become generalized. These include DYT-THAP1, DYT-TAF1, DYT-ATP1A3, DYT-KMT2B and rarely DYT-TORIA. Other OMDs with onset in adulthood remain focal or segmental (cranio-cervical). These include DYT-CIZ1, DYT-ANO3 and DYT-GNAL. DYT-COL6A3, DYT-HPC4 and DYT-VPS16 are recessively inherited isolated dystonia, with symptom onset from childhood to adulthood, and dystonia distribution from focal to generalized.

Jaw dystonia is a prominent feature in Lesch-Nyhan syndrome, associated classically with self-injurious behavior and cognitive and behavioral disturbances. However, attenuated variants presenting with predominant dystonia have been reported.[70] Neurodegeneration with brain iron accumulation (NBIA) syndromes should be considered in patients with childhood or early adulthood onset cranio-cervical dystonia.[71]

Associated features like Parkinsonism and pyramidal signs and radiological findings will point to the diagnosis. Jaw opening dystonia and facial dystonia have been described in type III GM1 gangliosidos, observed in >80% of patients.[72-74] These are also seen in Niemann-Pick disease type C,[75] GM2 gangliosidosis,[76] Cerebrotendinous xanthomatosis,[77] Tay-Sachs disease[78] and Ataxia telangiectasia.[79,80]

Dopa responsive dystonia due to GTP-CH1 deficiency classically presents in childhood with lower limb dystonia, but progression to generalized dystonia is commonly described and cranial-cervical involvement was found in 68% of patients in one study.[81] Rare cases with isolated oromandibular dystonia have also been described.[82] Other pediatric neurotransmitter disorders with dopa-responsive dystonia phenotype have oculogyric crisis as a classical clinical feature,[83] but lower cranial dystonia is also reported. These should be considered in the appropriate age group because of the excellent treatment response. Dopamine transporter deficiency syndrome also has oromandibular dystonia as a prominent feature.[84]

OMD has been described in various Spinocerebellar ataxias including SCA1,[85] SCA2,[86] SCA3,[87] SCA8,[88] SCA12[89] and SCA36.[90] OMD may occur during the course of the illness, or rarely, can be the presenting feature. Dystonia was present in 14% of SCA2 patients in a cohort and was found to be associated with larger repeats.[91]

Mitochondrial disorders can present with hypokinetic and hyperkinetic movement disorders. Dystonia is the commonest hyperkinetic movement disorder observed and is usually generalized or multifocal, although focal dystonia involving the cranial musculature has also been described. Patients with mitochondrial disorders presenting with dystonia are more likely to harbor mtDNA mutations.[92]

**Functional OMD**

Involvement of the face represents 16.3% of all functional movement disorders (FMD) in a large series of patients.[93] Facial involvement is generally characterized by an episodic onset, highly variable course, inconsistency of presentation over time, higher prevalence in women (9:1) and young-adult population, and association with other conditions like atypical facial pain and migraine and other functional neurological symptoms like speech disturbances and weakness ipsilateral to the most affected side of face. The most common pattern of facial FMDs consists of tonic, sustained, lateral, and/or downward protrusion of one side of the lower lip with ipsilateral jaw deviation, as found in 84.3% of the largest series published so far.[93]

Unlike organic OMD, most subjects have asymmetric facial involvement and absence of geste antagoniste. FMDs are usually present at rest right from the beginning, in contrast to the task-specific/action induced dystonia occurring in OMD.[94] FMDs involving the face can often be triggered by examination of eye movements or by asking the patients to sustain muscular contraction of the face.
OMD should be differentiated from local/mechanical disorders of the mandible or temporomandibular joint. The occurrence of local pain and a careful observation of the nature of functional impairment (e.g. chewing difficulty) helps in the differential diagnosis.

**Diagnostic Evaluation**

A detailed clinical history including drug history and the temporal evolution of dystonic and associated symptoms is key for evaluation of OMD as this provides useful information to tailor the investigations for the individual patient. Detailed physical examination to look for subtle dystonia elsewhere and for additional neurological signs should be done. Serum ceruloplasmin level and slit lamp exam to rule out Wilson’s disease should be performed for all patients who present in childhood, adolescence or early adulthood. MRI Brain is necessary in all cases, unless a clear drug history suggesting tardive dystonia is present. MRI should include SWI sequences to look for evidence of iron accumulation. Specific investigations, including genetic studies, can be further performed based on the clinical phenotype and radiological findings. The diagnostic approach depends on the age of the patient as the possible etiologies vary depending on age of onset. In the absence of history suggestive of tardive dystonia, heredo-degenerative conditions or conditions with structural brain damage are more likely in children and young adults even if the OMD is isolated at the time of presentation. Figures 1 and 2 show simplified diagnostic algorithms which can be followed in children and adults respectively, who present with OMD. Certain clinicoradiological clues can guide the differential diagnosis [Table 3] and should not be missed.

---

**Figure 1:** Approach to oromandibular dystonia with onset in childhood to early adulthood

**Figure 2:** Approach to oromandibular dystonia with onset in adulthood
Pathogenesis

Physiological studies of the somatotopic organization of the basal ganglia suggest that the lateral portion of the substantia nigra and the caudo-ventral portion of putamen and pallidum are primarily concerned with orolingual and head movement, and that the basal ganglia in one cerebral hemisphere play a role in bilateral orofacial-lingual motor control. Curra et al. using Transcranial Magnetic Stimulation (TMS) based studies, found that the cortical silent period from perioral muscles in patients with OMD is significantly shortened, compared to healthy volunteers. This indicates that reduced excitability of cortical inhibitory interneurons or reduced facilitation of inhibitory interneurons from subcortical or other cortical structures plays a role in the pathogenesis.

Treatment

OMD can significantly affect communication and swallowing function and it is important to address the social, emotional and nutritional impact of the disorder. A multidisciplinary

| Clinicoradiological clue | Disease |
|--------------------------|---------|
| Optic atrophy            | Leigh syndrome |
|                          | Methylmalonic aciduria |
|                          | Friedreich’s ataxia |
|                          | PLA2G6 associated neurodegeneration |
|                          | Pantothenate kinase associated neurodegeneration |
|                          | Mitochondrial membrane protein–associated neurodegeneration |
| Cataract                 | Wilson’s disease |
|                          | Cerebrotendinous xanthomatosis |
| Oculogyric crisis        | Tyrosine hydroxylase deficiency |
|                          | Sepiapterin reductase deficiency |
|                          | 6-pyruvoyl-tetrahydropterin synthase deficiency |
|                          | Aromatic L-amino acid decarboxylase deficiency |
|                          | Drug induced |
| Deafness                 | Leigh syndrome |
|                          | Dystonia-deafness syndrome |
|                          | Woodhouse-Sakati Syndrome |
|                          | Cerebrotendinous xanthomatosis |
| Self-injurious behavior[a](#) | Lesch-Nyhan syndrome |
|                          | Pantothenate kinase associated neurodegeneration |
|                          | Chorea-acanthocytosis |
|                          | Wilson’s disease |
|                          | 6-pyruvoyl-tetrahydropterin synthase deficiency |
|                          | Anti-NMDA encephalitis |
| Ataxia                   | Friedreich’s ataxia |
|                          | Ataxia telangiectasia |
|                          | Cerebrotendinous xanthomatosis |
|                          | Niemann-Pick type-C |
|                          | Aceruloplasminemia |
|                          | PLA2G6 associated neurodegeneration |
|                          | Pantothenate kinase associated neurodegeneration |
|                          | Wilson’s disease |
|                          | Spinocerebellar ataxias |
| Peripheral neuropathy    | Spinocerebellar ataxias – SCA 2, 3 |
|                          | Friedreich’s ataxia |
|                          | Niemann-Pick type-C |
|                          | Cerebrotendinous xanthomatosis |
|                          | GM2 gangliosidosis |
|                          | PLA2G6 associated neurodegeneration |
|                          | Mitochondrial membrane protein–associated neurodegeneration |
|                          | COASY protein–associated neurodegeneration |
| Hypogonadism             | Woodhouse Sakati syndrome |
|                          | Ataxia telangiectasia |

| Clinicoradiological clue | Disease |
|--------------------------|---------|
| Hepatic involvement      | Wilson’s disease |
|                          | Aceruloplasminemia |
|                          | Ataxia telangiectasia |
|                          | Niemann-Pick type-C |
|                          | Gaucher disease |
|                          | GM1 gangliosidosis |
|                          | McLeod syndrome |
|                          | Acquired hepatocerebral degeneration |
|                          | Coeliac disease |
| Renal dysfunction        | Leigh syndrome |
|                          | Methylmalonic aciduria |
|                          | Lesch Nyhan syndrome |
|                          | Wilson’s disease |
|                          | Glutaric aciduria type 1 |
|                          | Systemic lupus erythematosus |
| Brain iron accumulation on MRI | Pantothenate kinase associated neurodegeneration |
|                          | PLA2G6 associated neurodegeneration |
|                          | Aceruloplasminemia |
|                          | Neuroferritinopathy |
|                          | Woodhouse Sakati syndrome |
|                          | COASY protein–associated neurodegeneration |
|                          | GM1 gangliosidosis |
| T2 hyperintensities in Globus pallidus on MRI | Wilson’s disease |
|                          | Methylmalonic aciduria |
|                          | Leigh syndrome |
|                          | Extrapontine myelinolysis |
|                          | Japanese encephalitis |
|                          | Kernicterus |
|                          | Behcet syndrome |
|                          | Acquired hepatocerebral degeneration |
|                          | Carbon monoxide poisoning |

Table 3: Clinicoradiological clues for specific etiology

| Clinicoradiological clue | Disease |
|--------------------------|---------|
| Optic atrophy            | Leigh syndrome |
|                          | Methylmalonic aciduria |
|                          | Friedreich’s ataxia |
|                          | PLA2G6 associated neurodegeneration |
|                          | Pantothenate kinase associated neurodegeneration |
|                          | Mitochondrial membrane protein–associated neurodegeneration |
| Cataract                 | Wilson’s disease |
|                          | Cerebrotendinous xanthomatosis |
| Oculogyric crisis        | Tyrosine hydroxylase deficiency |
|                          | Sepiapterin reductase deficiency |
|                          | 6-pyruvoyl-tetrahydropterin synthase deficiency |
|                          | Aromatic L-amino acid decarboxylase deficiency |
|                          | Drug induced |
| Deafness                 | Leigh syndrome |
|                          | Dystonia-deafness syndrome |
|                          | Woodhouse-Sakati Syndrome |
|                          | Cerebrotendinous xanthomatosis |
| Self-injurious behavior[a](#) | Lesch-Nyhan syndrome |
|                          | Pantothenate kinase associated neurodegeneration |
|                          | Chorea-acanthocytosis |
|                          | Wilson’s disease |
|                          | 6-pyruvoyl-tetrahydropterin synthase deficiency |
|                          | Anti-NMDA encephalitis |
| Ataxia                   | Friedreich’s ataxia |
|                          | Ataxia telangiectasia |
|                          | Cerebrotendinous xanthomatosis |
|                          | Niemann-Pick type-C |
|                          | Aceruloplasminemia |
|                          | PLA2G6 associated neurodegeneration |
|                          | Pantothenate kinase associated neurodegeneration |
|                          | Wilson’s disease |
|                          | Spinocerebellar ataxias |
| Peripheral neuropathy    | Spinocerebellar ataxias – SCA 2, 3 |
|                          | Friedreich’s ataxia |
|                          | Niemann-Pick type-C |
|                          | Cerebrotendinous xanthomatosis |
|                          | GM2 gangliosidosis |
|                          | PLA2G6 associated neurodegeneration |
|                          | Mitochondrial membrane protein–associated neurodegeneration |
|                          | COASY protein–associated neurodegeneration |
| Hypogonadism             | Woodhouse Sakati syndrome |
|                          | Ataxia telangiectasia |

Table 3: Contd...

| Clinicoradiological clue | Disease |
|--------------------------|---------|
| Hepatic involvement      | Wilson’s disease |
|                          | Aceruloplasminemia |
|                          | Ataxia telangiectasia |
|                          | Niemann-Pick type-C |
|                          | Gaucher disease |
|                          | GM1 gangliosidosis |
|                          | McLeod syndrome |
|                          | Acquired hepatocerebral degeneration |
|                          | Coeliac disease |
| Renal dysfunction        | Leigh syndrome |
|                          | Methylmalonic aciduria |
|                          | Lesch Nyhan syndrome |
|                          | Wilson’s disease |
|                          | Glutaric aciduria type 1 |
|                          | Systemic lupus erythematosus |
| Brain iron accumulation on MRI | Pantothenate kinase associated neurodegeneration |
|                          | PLA2G6 associated neurodegeneration |
|                          | Aceruloplasminemia |
|                          | Neuroferritinopathy |
|                          | Woodhouse Sakati syndrome |
|                          | COASY protein–associated neurodegeneration |
|                          | GM1 gangliosidosis |
| T2 hyperintensities in Globus pallidus on MRI | Wilson’s disease |
|                          | Methylmalonic aciduria |
|                          | Leigh syndrome |
|                          | Extrapontine myelinolysis |
|                          | Japanese encephalitis |
|                          | Kernicterus |
|                          | Behcet syndrome |
|                          | Acquired hepatocerebral degeneration |
|                          | Carbon monoxide poisoning |

Contd...
approach combining medical treatment with speech therapy and nutrition management is important in addressing the needs of patients. Proper dental and oral evaluation is needed to assess orofacial and oropharyngeal function.\cite{98} Triggers (especially relevant to sensory tricks) and the subtype of OMD should be carefully identified.

Sensory tricks (geste antagoniste) do not seem to provide adequate long-term relief and mostly requires actions that interfere with normal functional activities. Sensory tricks like pressing the teeth or lips with the fingers, placing objects in the mouth, singing, or humming may be helpful in few patients. Oral appliances have also shown to be useful,\cite{99} especially when they mimic the patient’s sensory tricks. Sensory tricks may work better for jaw-opening dystonia rather than jaw-closing dystonia.\cite{100}

Pharmacological treatment of OMD is mostly based on empirical experience rather than supported by rational scientific evidence.\cite{101} Oral medications are seldom beneficial in improving dystonic symptoms. The oral medications which can be tried include anticholinergic drugs, baclofen, dopaminergic drugs, and benzodiazepines. Tetrabenazine is reported to be useful in 26–60% of OMD patients but is associated with side effects like parkinsonism, depression and suicidal ideation.\cite{102}

Chemodenervation with botulinum toxin (BTX) is considered by most to be the first line of treatment. However, there are no supporting high-level clinical trials, and the evidence is mainly based on small series of cases. Abobotulinumtoxin A and onabotulinumtoxin A have level C evidence according to the American Academy of Neurology Classification for the Quality of Evidence; for incobotulinumtoxin A and rimabotulinumtoxin B, it is level U (inadequate data/still unproven).\cite{103} Empirical experience over past 20 years has shown BTX to be an effective and safe approach in the treatment of OMD.\cite{104} Jaw closure dystonia tends to respond better to BTX than jaw-opening or mixed dystonia.\cite{105} BTX has been found to be equally effective in tardive as well as idiopathic OMD.

For OMD refractory to medical management, Deep brain stimulation targeting the globus pallidus internus has been shown to be effective in case series, but the evidence is still preliminary.\cite{105,106}

**Conclusions**

Oromandibular dystonia is a rather common movement disorder and causes significant interference with functioning because of its impact on speech and swallowing functions. Genetic and presumed genetic (idiopathic), and tardive etiologies account for the majority of isolated OMD in adulthood. In an isolated generalized dystonia or a combined dystonia syndrome, presence of prominent oro-mandibular involvement often helps to narrow down the list of differentials. Management of OMD may need a multidisciplinary approach. BTX provides relief in the majority of patients.

**Financial support and sponsorship**
Nil.

**Conflicts of interest**
There are no conflicts of interest.

**References**

1. Termsarasab P, Tanenbaum DR, Frucht SJ. The phenomenology and natural history of idiopathic lower cranial dystonia. J Clin Mov Disord 2014;1:3.

2. Tan EK, Jankovic J. Botulinum toxin A in patients with oromandibular dystonia: Long-term follow-up. Neurology 1999;53:2102-7.

3. Pandey S, Sharma S. Meige’s syndrome: History, epidemiology, clinical features, pathogenesis and treatment. J Neurol Sci 2017;372:162-70.

4. Nutt JG, Mueenter MD, Aronson A, Kurland LT, Melton LJ 3rd. Epidemiology of focal and generalized dystonia in Rochester, Minnesota. Mov Disord 1988;3:188-94.

5. Slaim L, Cohen M, Klap P, Vidalhiet M, Perrin A, Brasnu D, et al. Oromandibular dystonia: Demographics and clinical data from 240 patients. J Mov Disord 2018;11:78-81.

6. Sex-related influences on the frequency and age of onset of primary dystonia. Epidemiologic Study of Dystonia in Europe (ESDE) Collaborative Group. Neurology 1999;53:1871-3.

7. Tolosa E, Martí MJ. Blepharospasm-oromandibular dystonia syndrome (Meige’s syndrome): Clinical aspects. Adv Neurol 1988;49:73-84.

8. Tan EK, Jankovic J. Tardive and idiopathic oromandibular dystonia: A clinical comparison. J Neurol Neurosurg Psychiatry 2000;68:186-90.

9. Espinosa B, Freeman A, Factor SA. Lingual protrusion dystonia: Frequency, etiology and botulinum toxin therapy. Parkinsonism Relat Disord 2010;16:438-41.

10. Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn S, Fung VS, et al. Phenomenology and classification of dystonia: A consensus update. Mov Disord 2013;28:863-73.

11. Donaldson I, Marsden CD, Schneider SA, Bhatia KP. Marsden’s Book of Movement Disorders. Idiopathic (primary) cranial dystonias: Oxford University Press; 2012.

12. Gonzalez-Alegre P, Schneider RL, Hoffman H. Clinical, etiological, and therapeutic features of jaw-opening and jaw-closing oromandibular dystonias: A decade of experience at a single treatment center. Tremor Other Hyperkinet Mov (N Y) 2014;4:231.

13. Clark GT, Ram S. Orofacial movement disorders. Oral Maxillofac Surg Clin North Am 2016;28:397-407.

14. Skärmeta NP, Espinoza-Mellado P, Chana P. Orofacial dystonia and other oromandibular movement disorders. In: Rizk TMG, editor. Dystonia. Rijeka: IntechOpen; 2018.

15. Frucht SJ, Fahn S, Greene PE, O’Brien C, Gelb M, Truong DD, et al. The natural history of embouchure dystonia. Mov Disord 2001;16:899-906.

16. Yatho TC, Jankovic J. The many faces of hemifacial spasm: Differential diagnosis of unilateral facial spasms. Mov Disord 2011;26:1582-92.

17. Thompson PD, Osesa JA, Delgado G, Gallego J, Marsden CD. Focal dystonia of the jaw and the differential diagnosis of unilateral jaw and masticatory spasms. J Neurol Neurosurg Psychiatry 1986;49:651-6.

18. Uvais NA, Sreeraj VS, Sathish Kumar SV. Sertraline induced mandibular dystonia and bruxism. J Family Med Prim Care 2016;5:882-4.

19. Mondet L, Radouble F, Gras V, Masmoudi K. Cefixime-induced oromandibular dystonia in an adult: A case report. Curr Drug Saf 2017. doi: 10.2174/157488631266170310095320.

20. Lizarroga KJ, Lopez MR, Singer C. Reversible craniovascular dystonia associated with levofloxacin. J Clin Mov Disord 2015;2:10.

21. Eisen I, Demirence S, Yis U, Kural S. Cetirizine-induced dystonic reaction in a 6-year-old boy. Pediatr Emerg Care 2008;24:627-8.

22. De Riu G, Sanna MP, De Riu PL. An elderly female patient with tardive oromandibular dystonia after prolonged use of the histamine analog betahistine. J Clin Neurosci 2010;17:1330-1.

23. Zhang R, Lai J, Huang J. Acute onset of orofacial dystonia from promethazine treatment: A case report. Medicine (Baltimore) 2019;98:e17675.
24. Kimber TE, Thompson PD. Segmental dystonia in the context of dextrothromboxanopha abn: A new cause of delayed onset drug-induced dystonia? Mov Disord Clin Pract 2015;2:299-300.

25. Jitrapakulsan J, Srivantaichapoon P. Acute dystonic reaction following general anesthetic agent use. Tremor Other Hyperkinet Mov (N Y) 2017;7:514.

26. Cengiz A, Aybay MN, Sarici SF, Oner V, Arslan FZ, Cengiz A. Capectiþolate-related neurotoxicity presenting as oromandibular dystonia. J Oncol Pract 2018;14:202-4.

27. Uzun ME, Korkmaz MF, Ekiçi A, Kaymaz N. Methylphenidate induced acute dystonic reaction. Indian J Pediatr 2018;85:577.

28. Das S, van Landeghem FKH. Clinicopathological spectrum of bilirubin encephalopathy/kernicterus. Diagnoses (Basel) 2019;9:294.

29. Seiser A, Schwarz S, Aichinger-Steiner MM, Funk G, Schneider P, Brainin M. Parkinsonism and dystonia in central pontine and extrapontine myelolysis. J Neurol Neurosurg Psychiatry 1998;65:119-21.

30. Wang HC, Cheng SJ. The syndrome of acute bilateral basal ganglia lesions in diabetic uremic patients. J Neurol 2003;250:948-955.

31. Ferrara J, Jankovic J. Acquired hepatocerebral degeneration. J Neurol 2009;256:320-32.

32. Hannawi Y, Abes MS, Geocadin RG, Mirski MA. Abnormal movements in critical care patients with brain injury: A diagnostic approach. Crit Care 2016;20:60.

33. Revilla FJ, Racette BA, Perlmuter JS. Chorea and jaw-opening dystonia as a manifestation of NeuroBechet's syndrome. Mov Disord 2000;15:741-4.

34. Pittock SJ, Parisi JE, McKeon A, Roemer SF, Lucchetti CF, Tan KM, et al. Paraneoplastic jaw dystonia and laryngospasm with antineural nuclear autoantibody type 2 (anti-Ri). Arch Neurolog 2010;67:1109-15.

35. Asalathara R, Kishore A, Sarada C, Nair MD. Satoyoshi syndrome. Neur India 2004;52:94-95.

36. Wicki J, Germanier Y, Sztajzel R, Burkhard PR. Brueghel syndrome as a new manifestation of HIV encephalopathy. Eur Neurol 2008;60:107-8.

37. Alarcon F, Duenas G, Cevallos N, Lees AJ. Movement disorders in adulthood. Brain 2014;137:1107-19.

38. Singer C, Lang AE, Suchoworsky O. Adult-onset subacute cerebellar penacepalephalitis: Case reports and review of the literature. Mov Disord 2009;17:1242-53.

39. Brandel JP, Vidalhiet M, Noseda G, Harpy JP, Agid Y. Myoclonus in ooromandibular dystonia: A manifestation of sporadic cases. J Neurol Neurosurg Psychiatry 1987;50:1228-9.

40. Kalita J, Misra UK, Pradhan PK. Oromandibular dystonia in basal ganglia syndromes. J Neurol Sci 2011;304:107-10.

41. Kim HJ, Lee MC, Kim JS, Chung SJ, Kim HJ, Kwon M, et al. Lingual dystonia as a manifestation of thalamic infarction. Mov Disord 2009;24:1703-4.

42. Salazar G, Espanol G, Fragoso M, Reyes A, Escalante J, Zegarra J. Progressive dystonia and spasticity. In: Fernandez HH, Merello M, editors. Movement Disorders: Unforeseeable Cases and Lessons from the Bedside. New York: Springer Publishing Company; 2012. p. 191-3.

43. Tan AH, Mah JSY, Thong MK, Lim S-Y. Methylmalonic aciduria: A treatable disorder of which adult neurologists need to be aware. Mov Disord Clin Pract 2016;3:104-5.

44. Ng J, Zhen J, Meyer E, Erreger K, Li Y, Kakar N, et al. Dopamine transporter deficiency syndrome: Phenotypic spectrum from infancy to adulthood. Brain 2014;137:1107-19.

45. Yapici Z, Tsusch K, Erakos M. Hypermetamnesia with dystonia 1: A novel mutation and response to iron supplementation. Mov Disord Clin Pract 2020;7:94-96.

46. Gantenbein AR, Damon-Perriere N, Bohlender JE, Chauve M, Latexgue C, Miranda A, et al. Feeding dystonia in McLeod syndrome. Mov Disord 2011;26:2123-6.

47. Kojovic M, Parees I, Lampreia T, Pienckz-Reclawowicz K, Xiromerisiou G, Rubio-Agusti I, et al. The syndrome of deafness-dystonia: Clinical and genetic heterogeneity. Mov Disord 2013;28:795-803.

48. Schneider SA, Bhatia KP. Secondary dystonia-clinical clues and syndromic associations. J Mov Disord 2009;2:58-63.

49. Blanchet PJ, Popovic R, Guitard F, Rompré PH, Lamarche C, Lavigne GJ. Pain and denture condition in edentulous oromandibular dystynthesis: Comparisons with tardive dyskinesia and control subjects. Mov Disord 2008;23:1837-42.

50. Berman BD, Groth CL, Sillau SH, Pirio Richardson S, Norris SA, Junker J, et al. Risk of spread in adult-onset isolated focal dystonia: A prospective international cohort study. J Neurol Neurosurg Psychiatry 2020;91:614-20.

51. Silverdale MA, Schneider SA, Bhatia KP, Lang AE. The spectrum of oorolingual tremor--a proposed classification system. Mov Disord 2008;23:159-67.

52. Martino D, Iuizzi D, Macerotto A, Aniello MS, Livrea P, Defazio G. The phenomenology of the geste antagonist in primary blepharospasm and cervical dystonia. Mov Disord 2010;25:407-12.

53. Molho ES, Feustel PJ, Factor SA. Clinical comparison of tardive and idiopathic cervical dystonia. Mov Disord 1998;13:486-9.

54. Petrovic IN, Kressevich N, Ganos C, Svetel M, Dragasevic N, Bhatia KP, et al. Characteristic “Forcible” geste antagonist in oromandibular dystonia resulting from pantothenate kinase-associated neurodegeneration. Mov Disord Clin Pract 2014;1:112-4.

55. Sankhla C, Lai EC, Jankovic J. Peripherally induced oromandibular dystonia. J Neurol Neurosurg Psychiatry 1998;65:722-8.

56. Frucht SJ. Embouchure dystonia--Portrat of a task-specific cranial dystonia. Mov Disord 2009;24:1752-62.

57. Sharma C, Kumawat BL, Garg A, Kumar Rana K. Chewing-induced facial dystonia: A rare presentation of task-specific dystonia. BMJ Case Rep 2017:2017. doi: 10.1136/bcr-2016-218956.

58. Scolding NJ, Smith SM, Sturman S, Brookes GB, Lees AJ. Auctioneer’s jaw: A case of occupational oromandibular hemidystonia. Mov Disord 1995;10:508-9.

59. Ilic TV, Pötter M, Holler I, Deuschl G, Volkman J. Praying-induced oromandibular dystonia. Mov Disord 2005;20:385-6.

60. Dietrichs E, Heier MS, Nakstad PH. Jaw-opening dystonia presumably caused by a pontine lesion. Mov Disord 2000;15:1026-8.

61. Dalmau J, Graus F, Villarejo A, Posner JB, Blumenthal D, Thiessen B, et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain 2004;127:1831-44.

62. Honarat JA, Komorowski L, Josephs KA, Fechner K, St Louis EK, Hinson SR, et al. IgLON5 antibody: Neurological accompaniments and outcomes in 20 patients. Neurol Neuroimmunol Neuroinflamm 2017;4:e385.

63. Tarabzouni S, Alikhairallah T. Isolated neurological manifestation in silent celiac disease. J Mov Disord 2017;10:105-7.

64. Papageorgiou SG, Kontaxis T, Bonakis A, Kalfakis N. Orofacial dystonia related to Sjögren’s syndrome. Clin Rheumatol 2007;26:1779-81.

65. Wu K, Christodoulou L, Siddiqui A, D’Cruz D, Andrews T. Bilateral reversible basal ganglia changes associated with dystonia and hemifacial spasm in central nervous system lupus. Quant Imaging Med Surg 2015;5:928-9.

66. Raoofi S, Khorsheidhi H, Najafi M. Etiology, diagnosis and management of oromandibular dystonia: An update for stomatologists. J Dent (Shiraz) 2015;28:795-803.
Saraf, et al.: Oromandibular dystonia – A review

Annals of Indian Academy of Neurology ¦ Volume 25 ¦ Issue 1 ¦ January‑February 2022

Disord 2005;20:1366‑9.
74. Muthane U, Chickbasaviah Y, Kaneski C, Shankar SK, Narayanappa G, Christopher R, et al. Clinical features of adult GM1 gangliosidosis: Report of three Indian patients and review of 40 cases. Mov Disord 2004;19:1334‑41.
75. Koen LH, Kuiper A, Coenen MA, Elting JWJ, de Vries JJ, Engelen M, et al. Ataxia, dystonia and myoclonus in adult patients with Niemann‑Pick type C. Orphanet J Rare Dis 2016;11:121.
76. Nardocci N, Bertagnolio B, Rumi V, Angelini L. Progressive dystonia symptomatic of juvenile GM2 gangliosidosis. Mov Disord 1992;7:64‑7.
77. Alcalay R, Wu S, Patel S, Frucht S. Oromandibular dystonia as a complication of cerebrotendinous xanthomatisos. Mov Disord 2009;24:1397‑9.
78. Grim KK, Phillips GD, Renner DR. Dysarthria and stutter as presenting symptoms of late‑onset tay‑sachs disease in three siblings. Mov Disord Clin Pract 2015;2:289‑90.
79. Carrillo F, Schneider SA, Taylor AM, Srinivasan V, Kapoor R, Bhatia KP. Prominent oromandibular dystonia and pharyngeal telangiectasia in atypical ataxia telangiectasia. Cerebellum 2009;8:22‑7.
80. Vidalhiet M, Anheim M, Hubsch C. Dysarthria, dystonia, and cerebellar ataxia: The tale of four sisters. In: Fernandez HH, Merello M, editors. Movement Disorders: Unforgettable Cases and Lessons from the Bedside. New York: Springer Publishing Company; 2012. p. 194‑5.
81. Trender‑Gerhard I, Sweeney MG, Schwingenschuh P, Mir P, Edwards MJ, Gerhard A, et al. Autosomal‑dominant GTPCH1‑deficient DRD: Clinical characteristics and long‑term outcome of 34 patients. J Neurol Neurosurg Psychiatry 2009;80:839‑45.
82. Steinberger D, Topka H, Fischer D, Muller U. GCH1 mutation in a patient with adult‑onset oromandibular dystonia. Neurology 1999;52:877‑9.
83. Wijemanne S, Jankovic J. Dopa‑responsive dystonia‑‑clinical and molecular characterisation of hereditary dopamine transporter deficiency syndrome: An observational cohort and experimental study. Lancet Neurol 2011;10:54‑62.
84. Wu YR, Lee‑Chen GJ, Lang AE, Chen CM, Lin HY, Chen ST. Dystonia as a presenting sign of spinocerebellar ataxia type 1. Mov Disord 2004;19:586‑7.
85. Antenora A, Peluso S, Sacca F, De Michele G, Filla A. Jaw‑opening oromandibular dystonia associated with spinocerebellar ataxia type 2. Mov Disord Clin Pract 2014;1:121‑2.
86. Catai LMP, Camargo CHF, Moro A, Ribas G, Raskin S, Teive HAG. Dystonia in patients with spinocerebellar ataxia 3‑Machado‑Joseph disease: An underestimated diagnosis? Open Neurol J 2018;12:41‑9.
87. Ushe M, Perlmutter JS. Oromandibular and lingual dystonia associated with spinocerebellar ataxia type 8. Mov Disord 2012;27:1741‑2.
88. Ganos C, Saifee TA, Kassavetis P, Erro R, Batla A, Cordivari C, et al. Dystonic tremor and spasmodic dysphonia in spinocerebellar ataxia type 12. Mov Disord Clin Pract 2014;1:79‑81.
89. Ganos C, Saifee TA, Kassavetis P, Erro R, Batla A, Cordivari C, et al. Autosomal‑dominant dystonia associated with SCA36. Mov Disord 2013;28:558‑9.
90. van Gaalen J, Giunti P, van de Warrenburg BP. Movement disorders in spinocerebellar ataxias. Mov Disord 2011;26:792‑800.
91. Martikainen MH, Ng YS, Gorman GS, Alston CL, Blakely EL, Schaefer AM, et al. Clinical, genetic, and radiological features of extrapyramidal movement disorders in mitochondrial disease. JAMA Neurol 2016;73:668‑74.
92. Fasano A, Valadas A, Bhatia KP, Prashanth KL, Lang AE, Munhoz RP, et al. Psychogenic facial movement disorders: Clinical features and associated conditions. Mov Disord 2012;27:1544‑51.
93. Fasano A, Tinazzi M. Functional facial and tongue movement disorders. Handb Clin Neurol 2016;139:353‑65.
94. Fischer JF, Mainka T, Worbe Y, Pringsheim T, Bhatia K, Ganos C. Self‑injurious behaviour in movement disorders: Systematic review. J Neurol Neurosurg Psychiatry 2020;91:712‑9.
95. Jankovic J. Cranial‑cervical dyskinesias: An overview. Adv Neurol 1988;49:1‑13.
96. Curra A, Romaniello A, Berardelli A, Crucu G, Manfredi M. Shortened cortical silent period in facial muscles of patients with cranial dystonia. Neurology 2000;54:130‑5.
97. Karp BI, Alter K. Botulinum toxin treatment of blepharospasm, orofacial/omandibular dystonia, and hemifacial spasm. Semin Neurol 2016;36:84‑91.
98. Lo SE, Gelb M, Frucht SJ. Geste antagonistes in idiopathic lower cranial dystonia. Mov Disord 2007;22:1012‑7.
99. Singer C, Papapetropoulos S. A comparison of jaw‑closing and jaw‑opening idiopathic oromandibular dystonia. Parkinsonism Relat Disord 2006;12:115‑8.
100. Jankovic J. Medical treatment of dystonia. Mov Disord 2013;28:1001‑12.
101. Jankovic J, Beach J. Long‑term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997;48:358‑62.
102. Simpson DM, Hallett M, Ashman EJ, Cornella CL, Green MW, Gronseth GS, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2016;86:1818‑26.
103. Ramirez‑Castaneda I, Jankovic J. Long‑term efficacy, safety, and side effect profile of botulinum toxin in dystonia: A 20‑year follow‑up. Toxicon 2014;90:344‑8.
104. Sako W, Morigaki R, Mizobuchi Y, Tsuzuki T, Ima H, Ushio Y, et al. Bilateral pallidal deep brain stimulation in primary Meige syndrome. Parkinsonism Relat Disord 2011;17:123‑5.
105. Inoue N, Nagahiro S, Kaji R, Goto S. Long‑term suppression of Meige syndrome after pallidal stimulation: A 10‑year follow‑up study. Mov Disord 2010;25:1756‑8.